NEW YORK (GenomeWeb) – Myriad Genetics reported after the close of the market Tuesday that its fourth quarter revenues rose 8 percent year over year.

The Salt Lake City-based molecular diagnostics firm brought in total revenues of $188.8 million for the three months ended June 30, compared to revenues of $174.1 million for the fourth quarter of 2013, beating the consensus Wall Street estimate of $187.7 million.

The firm's shares fell in Wednesday morning trade, however, after Myriad provided guidance for Fiscal Year 2015 below analysts' estimates.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: Icelandic genome sequences, approach to increase CRISPR efficiency, and more.

Testing showing "genetic incompatibilities" have led thousands of couples in Saudi Arabia to call off their weddings, the BBC reports.

Decode Genetics' ability to tell Icelanders, even ones the company hasn't sequenced, about their disease risk brings up ethical questions.

Genetic analysis of Britain's King Richard III and modern descendants of his relatives indicate breaks in the male line.